The ADDORA-studies

Previous research showed that serum drug levels differ largely between patients using the same dosages of a biologic. Higher drug levels are not more beneficial. However, they may increase the risk for infections and side-effects and make treatment more expensive.

Therefore the Sint Maartenskliniek, together with Reade Amsterdam, started with three trials. In these trials we aim to optimalise treatment for rheumatoid arthritis patients by measuring serum drug levels.

The trials started august 2020, and are expected to finish 2023. We are looking for patients that:

• Start treatment with adalimumab (ADDORA)
• Use adalimumab and start tapering (ADDORA-low)
• Use adalimumab but are about to stop due to inefficiency (ADDORA-switch)

In the ADDORA trials we collaborate with:

• Reade Amsterdam
• Sanquin Diagnostics lab Amsterdam.